Astrocyte responses to postnatal erythropoietin and nano-erythropoietin treatments in a valproic acid-induced animal model of autism.

Scientists tested whether a protein called erythropoietin (EPO) could help with autism-like behaviors in baby rats. They gave pregnant rats a drug that causes autism-like changes in their babies, then treated the newborn rats with EPO for 5 days. The treated rats showed fewer repetitive behaviors and less brain inflammation compared to untreated rats. A special form of EPO wrapped in tiny particles worked better, possibly because it gets into the brain more easily.

This animal study examined whether postnatal erythropoietin (EPO) treatment could improve autism-like behaviors in rats exposed to valproic acid during pregnancy. Researchers compared regular EPO with nano-encapsulated EPO (NEPO), which may better cross the blood-brain barrier. Male offspring received treatments for 5 days after birth and were later tested for repetitive behaviors using marble burying tests. Brain tissue was examined for astrocyte activation markers (GFAP and S100B) in the prefrontal cortex and hippocampus.

Results showed that VPA-exposed rats displayed more repetitive behaviors and increased brain inflammation. NEPO treatment, particularly at higher doses, reduced repetitive behaviors and brain inflammation compared to untreated VPA animals, suggesting potential therapeutic benefits for early autism intervention.

While promising for understanding autism neurobiology, this early-stage animal research requires extensive human safety and efficacy studies before clinical application. The nano-encapsulation approach may inform future drug delivery strategies, but translation to human infants would require careful consideration of safety and developmental factors.

Single animal model study with unclear sample sizes. Limited behavioral assessment using only marble burying test. Short treatment duration (5 days) with unclear long-term effects. No comparison to established treatments or placebo controls beyond untreated VPA groups.

Despite ample evidence of the potential protective effects of erythropoietin (EPO) on the developing brain, no study has addressed the effects of postnatal EPO on behaviors and brain tissue of animal models of autism. In the present study, we examined the therapeutic effects of postnatal erythropoietin on stereotypic behaviors and astrocyte responses via glial fibrillary acidic protein (GFAP) and S100 calcium-binding protein B (S100B) immunohistochemistry in a valproic acid (VPA) animal model of autism. Also, we compared the effects of EPO with EPO-loaded solid lipid nanoparticles (NEPO) because the blood-brain barrier has limited permeability to EPO. Pregnant rats received a single dose of VPA (600 mg/kg) at gestational day 12.5.

EPO (2000 U/kg) and EPO-loaded solid lipid nanoparticles (NEPO1000 and 2000 U/kg) were injected intraperitoneally from postnatal days 1-5. Repetitive behaviors in male offspring were assessed by a marble burying test. The immune-staining method was performed to evaluate S100B and GFAP-positive cells in the prefrontal cortex and hippocampal CA1 region. VPA animal models revealed more repetitive behavior and displayed higher astrogliosis in the prefrontal cortex (PFC) and hippocampus (CA1) regions.

The repetitive behaviors were ameliorated relatively in VPA groups with NEPO2000 treatment, and astrogliosis was reduced even when VPA rats were treated with a lower dosage of NEPO. Our results indicate beneficial effects of postnatal NEPO exposure in the VPA animal model of autism, which proposes it as an early treatment in infants with, or at risk of, autism.